Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)
Vir Biotechnology (VIR) reported Preferred Stock Liabilities of $636.6 million for Q3 2019, up 105.93% on a YoY basis from $309.1 million in Q3 2018, and little changed sequentially from $636.6 million in Q2 2019.
Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
Vir Biotechnology (VIR) has 2 years of Preferred Stock Liabilities data on file, last reported at $636.6 million in Q3 2019.
- For the quarter ending Q3 2019, Preferred Stock Liabilities rose 105.93% year-over-year to $636.6 million; the trailing twelve-month figure through Sep 2019 stood at $636.6 million (up 105.93% YoY), and the FY2018 full-year result was $309.1 million, up 5.68% from the prior year.
- Preferred Stock Liabilities steadied at $636.6 million in Q3 2019, from $636.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $636.6 million in Q2 2019 to a low of $309.1 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vir Biotechnology | 1.38 Bn | 1.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 636.61 Mn |
| Jun 30, 2019 | 636.61 Mn |
| Dec 31, 2018 | 309.14 Mn |
| Sep 30, 2018 | 309.14 Mn |